公司資料
Outlook 股價、新聞與催化劑
- 股票代碼:
- OTLK
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
0.67 USD (-11.13%)
收盤價
最後更新: 2026年8月17日
121M USD
市值
股價為何變動
Following the latest company update, “Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™”, OTLK closed down 14.9% at $0.7564 on Aug 14, 2026. The move occurred in the trading session associated with this fda / regulatory update.
公司概覽
Ophthalmic Bevacizumab Company
Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for oncology use.
LYTENAVA for Wet AMD
LYTENAVA, or bevacizumab-vikg in the United States and bevacizumab gamma in Europe, is a VEGF inhibitor approved for neovascular age-related macular degeneration. By binding VEGF-A, it is intended to suppress abnormal blood-vessel growth and vascular leakage that contribute to progressive vision loss.
US Commercial Franchise
LYTENAVA is the first and only FDA-approved ophthalmic formulation of bevacizumab for wet AMD. Outlook is establishing US market access, reimbursement, supply, medical-affairs, patient-support, and retina-specialist commercial capabilities ahead of product availability.
International Commercialization
LYTENAVA is also authorized in the European Union and United Kingdom and has been launched in Germany, Austria, and the UK. Outlook is pursuing additional country launches directly and through regional distribution partners.
未來催化劑
- Commercial launch of LYTENAVA in the United States before the end of 2026.
- Commercial launch of LYTENAVA in the Netherlands later in 2026.
- Potential Swiss approval and partner-led commercial launch of LYTENAVA in 2027.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。